Rodler ET - Search Results

1

A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.

Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN. Bremjit PJ, et al. Among authors: rodler et. Ann Surg Oncol. 2014 Jul;21(7):2150-8. doi: 10.1245/s10434-014-3616-7. Epub 2014 Mar 11. Ann Surg Oncol. 2014. PMID: 24615180 Clinical Trial.

2

Immune-based therapies for sarcoma.

Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Pollack SM, et al. Among authors: rodler et. Sarcoma. 2011;2011:438940. doi: 10.1155/2011/438940. Epub 2011 Jan 23. Sarcoma. 2011. PMID: 21331153 Free PMC article.

3

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.

Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. Pollack SM, et al. Among authors: rodler e. Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22. Cancer. 2012. PMID: 22359263 Free PMC article.

4

NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. Pollack SM, et al. Among authors: rodler e. PLoS One. 2012;7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27. PLoS One. 2012. PMID: 22384167 Free PMC article.

5

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.

Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Kurland BF, et al. Among authors: rodler et. EJNMMI Res. 2012 Jun 25;2(1):34. doi: 10.1186/2191-219X-2-34. EJNMMI Res. 2012. PMID: 22731662 Free PMC article.

6

Systemic therapy in primary angiosarcoma of the spleen.

Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Ferreira BP, et al. Among authors: rodler et. Rare Tumors. 2012 Oct 10;4(4):e55. doi: 10.4081/rt.2012.e55. Epub 2012 Nov 13. Rare Tumors. 2012. PMID: 23372919 Free PMC article.

7

The evolution of systemic therapy in sarcoma.

Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. Constantinidou A, et al. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23. doi: 10.1586/era.12.161. Expert Rev Anticancer Ther. 2013. PMID: 23406562 Review.

8

Clinical benefit of trabectedin in uterine adenosarcoma.

Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Schroeder BA, et al. Among authors: rodler et. Med Oncol. 2013 Jun;30(2):501. doi: 10.1007/s12032-013-0501-3. Epub 2013 Feb 28. Med Oncol. 2013. PMID: 23456619

9

Treatment of chest wall sarcomas: a single-institution experience over 20 years.

Burt A, Berriochoa J, Korpak A, Rodler E, Jones RL, Weisstein J, Patel S. Burt A, et al. Am J Clin Oncol. 2015 Feb;38(1):80-6. doi: 10.1097/COC.0b013e31828aac22. Am J Clin Oncol. 2015. PMID: 23563212

10

Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.

Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. Meyer JM, et al. Among authors: rodler et. Clin Cancer Res. 2013 Dec 15;19(24):6902-11. doi: 10.1158/1078-0432.CCR-13-1594. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132922 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters